Drugs / Hydromorphone
Hydromorphone
also known as
Dilaudid · hydromorphone hydrochloride · OROS hydromorphone · Hydromorphone HCI · Hydromorphone HCL · OROS hydromorphone HCI (slow release) · OROS hydromorphone HCL · Dilaudid CR · +31 more
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DILAUDID-HP | — | 2009-04-30 | fda.gov ↗ |
| Approved | US (FDA) | DILAUDID-HP | — | 1984-01-11 | fda.gov ↗ |
Trials 123 · started per year
today
US approved 1984
1
2
1
4
1
5
2
2
1
3
3
6
5
3
4
8
8
4
6
4
4
6
5
7
3
7
5
5
4
3
1
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07489625 | Mar 2026 → Dec 2027 expected | — | Qinghai Red Cross Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05610072 | Dec 2022 → Mar 2026 | substance-related disorder | William Stoops | Completed | No outcome recorded |
| Phase 0 | NCT01866254 | May 2013 → Dec 2017 | — | Grace Shih, MD | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT04081376 | Nov → Dec 2019 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03933865 | Oct 2018 → Feb 2022 | opiate dependence | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02787928 | Apr 2016 → Dec 2017 | — | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 1 | NCT01642030 | Aug 2013 → Jul 2017 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01824524 | Dec 2011 → Aug 2012 | — | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01487564 | Oct 2011 → Jan 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01487512 | Mar → Jul 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT03768024 | Jun → Oct 2007 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00853554 | Dec 2002 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT00399295 | ? → Jun 1997 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00410878 | ? → Aug 1999 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00398957 | ? → Sep 1998 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07846020 | Jan 2027 → Jan 2032 expected | chronic pain syndrome | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06949059 | Jan 2025 → Dec 2026 expected | acute coronary syndrome | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00177060 | Oct 2003 → May 2007 | — | Hordinsky, Maria K., MD | Terminated | No outcome recorded Stop: Business |
| Phase 221 trials · 2 missed | ||||||
| Phase 2 | NCT07224620 | Nov 2025 → May 2026 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT06036797 | Sep → Oct 2023 | — | Maternal and Child Health Hospital of Hubei Province | Unknown | No outcome recorded |
| Phase 2 | NCT05579223 | Oct 2022 → Jan 2024 | anus disorder | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT05901441 | Jun 2022 → May 2023 | — | Maternal and Child Health Hospital of Hubei Province | Completed | No outcome recorded |
| Phase 2 | NCT05565495 | Jan 2022 → Sep 2024 overdue | — | Xiaobo Yang, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT04243954 | Apr → Oct 2020 | — | Fujian Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04036968 | Feb 2020 → Nov 2022 | substance-related disorder | Johns Hopkins University | Completed | Mixed |
| Phase 2 | NCT03767933 | Apr 2019 → Mar 2023 | musculoskeletal system disorder | University of Alberta | Completed | Missed primary |
| Phase 2 | NCT03098563 | Nov 2017 → Nov 2023 | osteoarthritis, knee | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02901275 | Dec 2016 → Mar 2020 | — | Johns Hopkins University | Completed | Mixed |
| Phase 2 | NCT02437669 | May 2015 → Apr 2018 | — | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02360371 | Apr 2015 → May 2020 | opioid abuse | Johns Hopkins University | Completed | Missed primary |
| Phase 2 | NCT02096003 | May 2014 → May 2017 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02044094 | Nov 2013 → Jul 2014 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01598506 | Sep 2013 → Feb 2014 | — | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT01598545 | Feb 2013 → Jun 2014 | — | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT01675778 | Oct 2011 → Oct 2012 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00305110 | Jan → Oct 2006 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00195910 | Oct 2004 → Jan 2005 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00398788 | ? → Nov 2001 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00411307 | ? → Oct 2001 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00992576 | Jan 2010 → Nov 2011 | constipation disorder | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2/3 | NCT00305058 | Jul 2005 → Mar 2007 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 333 trials · 2 met primary · 2 missed | ||||||
| Phase 3 | NCT04785768 | Jul 2021 → May 2024 | — | Fujian Cancer Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03933397 | Aug 2019 → May 2022 | sickle cell disease | Duke University | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT03375515 | Sep 2018 → Dec 2019 | — | Fujian Cancer Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05576675 | May 2018 → Mar 2022 | — | Xijing Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03214510 | Oct 2017 → Jul 2027 expected | hepatobiliary disorder | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02321319 | Mar 2017 → Feb 2019 | chronic pain syndrome | Mallinckrodt | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT02423876 | Mar 2015 → Jan 2022 | female reproductive organ cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 3 | NCT02084355 | Apr 2014 → Dec 2015 | cancer | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01709747 | Jun 2013 → Feb 2018 | chronic pain syndrome | Piramal Critical Care, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01709721 | Feb 2013 → Feb 2018 | chronic pain syndrome | Piramal Critical Care, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01447212 | Dec 2011 → Jun 2014 | heroin dependence | University of British Columbia | Completed | Mixed |
| Phase 3 | NCT01311895 | Jan → Nov 2011 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01205126 | Dec 2009 → Feb 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00474110 | Aug 2009 → Dec 2011 | mucositis | University of British Columbia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00803283 | Nov → Dec 2008 | — | Johnson & Johnson Taiwan Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT00825370 | Oct 2008 → May 2009 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00631319 | Feb 2008 → Apr 2009 | chronic pain syndrome | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00627367 | Dec 2007 → Mar 2008 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00549042 | Oct 2007 → Jan 2009 | chronic pain syndrome | Mallinckrodt | Completed | Met primary |
| Phase 3 | NCT00980798 | Oct 2007 → Nov 2008 | osteoarthritis, hip, osteoarthritis, knee | Janssen-Cilag International NV | Completed | Missed primary |
| Phase 3 | NCT00261495 | Mar 2006 → Apr 2008 | — | Janssen Pharmaceutica N.V., Belgium | Completed | Met primary |
| Phase 3 | NCT00125801 | Aug 2005 → May 2008 | neoplasm | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00365898 | Jul 2005 | chronic pain syndrome | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00411164 | Nov 2003 → May 2005 | osteoarthritis, hip, osteoarthritis, knee | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00003115 | Jun 1996 → Jan 2003 | prostate cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00410748 | ? → Jun 2000 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00410644 | ? → Feb 1999 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00410540 | ? → May 2001 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00411268 | ? → Jun 2001 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00410943 | ? → Jun 1999 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00410787 | ? → Apr 2002 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00411034 | ? → Sep 1999 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00399048 | ? → May 2001 | osteoarthritis, hip, osteoarthritis, knee | Alza Corporation | Completed | No outcome recorded |
| Phase 431 trials · 3 met primary · 1 missed | ||||||
| Phase 4 | NCT06784180 | Feb 2026 → Jan 2029 | opiate dependence | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06823180 | Mar → Aug 2025 | — | Liquan Liang | Completed | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06669650 | Sep 2024 → Dec 2025 overdue | opiate dependence | University of Tennessee Graduate School of Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06525740 | Sep 2024 → Sep 2029 expected | female reproductive organ cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06495632 | Aug 2024 → Jul 2026 overdue | — | Cape Fear Valley Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT07315022 | Aug 2024 → Aug 2025 | — | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT05848635 | May 2023 → May 2024 | pulmonary coin lesion | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05708521 | Apr 2023 → May 2024 overdue | neuropathy, painful, substance-related disorder | Nova Scotia Health Authority | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05552443 | Mar 2023 → Oct 2024 | — | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT04752033 | Mar 2021 → Feb 2023 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03592992 | Nov 2020 → Jul 2022 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Met primary |
| Phase 4 | NCT04296305 | Sep 2020 → Dec 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04436224 | Sep 2020 → Mar 2025 | — | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 4 | NCT04258631 | Jul 2020 → Aug 2023 | female reproductive system neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04396587 | May 2020 → Jan 2023 | substance-related disorder | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04111328 | Oct 2019 → Sep 2020 | — | Jun Wang | Completed | Met primary |
| Phase 4 | NCT03648008 | May → Sep 2018 | neuropathy, painful | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT02939209 | Apr 2017 → May 2022 | rotator cuff syndrome | Vishal Uppal | Completed | Missed primary |
| Phase 4 | NCT01812759 | Jan → Oct 2014 | pain agnosia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 4 | NCT02067520 | Jan → Dec 2014 | — | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT01892709 | Jun 2013 → Apr 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01621100 | Dec 2011 → Sep 2012 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT01648699 | Apr → Sep 2010 | — | Janssen Pharmaceutica | Terminated | No outcome recorded |
| Phase 4 | NCT01429298 | Mar → Nov 2010 | — | Montefiore Medical Center | Completed | Met primary |
| Phase 4 | NCT01429285 | Jul 2009 → Jun 2012 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01006356 | Oct 2008 → Aug 2009 | cancer | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00766831 | Oct 2008 → Jun 2010 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00682435 | Aug → Nov 2007 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00465647 | Apr 2007 → May 2009 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase not applicable17 trials · 1 met primary | ||||||
| — | NCT06240390 | May → Aug 2024 | neuropathy, painful | Universidad Europea de Canarias | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT06218160 | Nov 2022 → Nov 2023 | — | Second Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT06205199 | Oct 2022 → Nov 2023 | — | Second Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT05375916 | May 2022 → Nov 2023 | substance-related disorder | University of Alberta | Completed | No outcome recorded |
| — | NCT04566250 | Feb 2021 → Apr 2022 | — | McMaster University | Completed | Met primary |
| — | NCT04044820 | Mar 2019 → Dec 2026 expected | substance-related disorder | University Health Network, Toronto | Recruiting | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT03478423 | Feb 2018 → Sep 2019 | — | Mount Sinai Hospital, Canada | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02880800 | Aug 2016 → Aug 2017 | neuropathy, painful | Mount Sinai Hospital, Canada | Unknown | No outcome recorded |
| — | NCT02789969 | Apr 2016 → Mar 2017 | — | St. Louis Children's Hospital | Unknown | No outcome recorded |
| — | NCT02277782 | Sep 2015 → Dec 2019 | pregnancy disorder | Brigham and Women's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01123486 | Jan 2015 | respiratory underresponsiveness to hypoxia and hypercapnia | Northwestern University | Withdrawn | No outcome recorded |
| — | NCT02205983 | Jan 2015 → Jul 2016 | — | University of Chicago | Completed | No outcome recorded |
| — | NCT01447888 | Sep 2011 → Mar 2014 | — | Allina Health System | Completed | No outcome recorded |
| — | NCT01442818 | Sep 2010 → Sep 2011 | — | TriHealth Inc. | Completed | No outcome recorded |
| — | NCT00413582 | Oct 2006 → May 2010 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00158236 | Jan 1997 → Mar 1998 | opioid abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Comparator or background therapy120 trials | ||||||
| Phase 0 | NCT06617949 Comparator | Jan 2025 → Dec 2027 expected | substance-related disorder | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT04230681 Comparator | Feb 2020 → Apr 2022 | obstructive sleep apnea syndrome, tonsillitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03579446 Background | Nov 2018 → Jun 2023 | hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT03088306 Comparator | Jul 2017 → May 2018 | lumbar disk degenerative disorder, lumbar spinal stenosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT06406400 Background | May → Jul 2024 | opiate dependence | AstraZeneca | Terminated | No outcome recorded |
| Show all 120 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2016-12-14 | Acura Pharmaceuticals Inc. | Results Acura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology acurapharm.com ↗
In Study AP-LTX-400 (Study 400), the LTX-04 tablets delivered approximately 50% of the maximum drug concentration in the blood stream (Cmax) following intended 1 and 2 tablet doses compared to DILAUDID. |
| 2016-06-08 | Acura Pharmaceuticals Inc. | Results Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities acurapharm.com ↗
LTX-04P tablets, a hydromorphone hydrochloride immediate-release tablet using the Company's new LIMITX oral abuse deterrent technology, successfully retarded the release of the active opioid ingredient when four, six and eight intact tablets were ingested. |
| 2016-04-13 | Acura Pharmaceuticals Inc. | Results Acura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence acurapharm.com ↗
However, the 3 tablet LTX-04P dose achieved an average stomach acid pH of 4.7 post-dose and the Cmax was only 3.8 times as high as the single tablet dose, an estimated 22% reduction in Cmax. |
| 2016-02-01 | Acura Pharmaceuticals Inc. | Regulatory Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology acurapharm.com ↗
clinical testing of its lead LIMITX™ oral abuse deterrent drug candidate using the opioid hydromorphone HCl (LTX-04) is allowed to proceed under an Investigational New Drug Application (IND) |
| 2009-12-10 | Lannett Company, Inc. | Regulatory Lannett Receives FDA Approvals For Hydromorphone Hydrochloride Tablets USPPDF Version investorroom.com ↗
it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg |
All press releases naming this drug 9 releases
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 251 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hydromorphone | “This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗228“The ice packs, Tylenol, and Toradol regimen consists of around-the-clock ice packs, around-the-clock oral acetaminophen, around-the-clock intravenous ketorolac, and intravenous...” PMID 31201808 ↗ Jun 2019 “Intraoperative analgesia using short-acting opioids (e.g., fentanyl and/or hydromorphone) administered at induction and throughout surgery according to clinician judgment and...” NCT07565870 ↗ “Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the...” NCT06429657 ↗ “The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose.” NCT03972397 ↗ “patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose).” NCT00413582 ↗ “Participants (N = 21; 57% women; mean age = 63.4 ± 6.4 yr) with knee osteoarthritis received oral combinations of placebo, hydromorphone (2 mg), and dronabinol (10 mg).” PMID 41481837 ↗ Dec 2025 “Total IntraVenous Anesthesia - to achieve deep-sedation via chemical analgesic (propofol, dexmedetomidine, fentanyl, hydromorphone); continuous intravenous infusion.” NCT07672301 ↗ “PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case.” NCT05693675 ↗ “The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.” NCT03393117 ↗ “Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone.” NCT03471442 ↗ |
| Known as | Dilaudid | “This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗18“The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose.” NCT03972397 ↗ “Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex.” NCT00547664 ↗ “Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.” NCT01447888 ↗ “Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.” NCT03458598 ↗ “Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI)” NCT00410943 ↗ “If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid” NCT02219581 ↗ “Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.” NCT03052816 ↗ “injectable hydromorphone (HDM; trade name Dilaudid™)” NCT01447212 ↗ “FDA-approved opioid hydromorphone (Dilaudid; oral)” NCT04036968 ↗ “The PCA drug will be Dilaudid (hydromorphone).” NCT02111746 ↗ |
| Known as | Dilaudid CR | “An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)” NCT00399048 ↗1“Dilaudid CR (Hydromorphone HCI)” NCT00411268 ↗ |
| Known as | Dilaudid CR (controlled release) | “A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain” NCT00398788 ↗ |
| Known as | Dilaudid OROS | “Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗ |
| Known as | Dilaudid Slow Release | “Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗ |
| Known as | Dilaudid SR | “A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR( Hydromorphone HCI) in Patients With Chronic Cancer Pain” NCT00411034 ↗1“Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain” NCT00410787 ↗ |
| Known as | Dilaudid SR Tablets | “A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain” NCT00410878 ↗1“Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI)” NCT00410943 ↗ |
| Known as | Dilaudid-hp | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | Dimorphone | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | Exalgo | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | HDM | “injectable hydromorphone (HDM; trade name Dilaudid™)” NCT01447212 ↗ |
| Known as | Hidromorfona | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | Hydromorph Contin | “Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID” NCT03990038 ↗ |
| Known as | Hydromorphon | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | hydromorphone ER | “OBJECTIVE: This multicenter, double-blind, placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER...” PMID 20429852 ↗ Jun 2010 |
| Known as | Hydromorphone HCI | “A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in...” NCT00399048 ↗3“OROS Hydromorphone HCI (slow release)” NCT00411034 ↗ “appropriate dose of hydromorphone HCI” NCT00410943 ↗ “OROS Hydromorphone HCI (slow release)” NCT00410878 ↗ |
| Known as | Hydromorphone HCL | “A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain” NCT00398788 ↗3“Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication.” NCT03541759 ↗ “Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.” NCT01006356 ↗ “Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗ |
| Known as | hydromorphone hydrochloride | “Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation” NCT05848635 ↗6“Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS)” NCT01006356 ↗ “hydromorphone hydrochloride 4 milligrams” NCT03757559 ↗ |
| Known as | Hydromorphone hydrochloride cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | Hydromorphone Hydrochloride Injection | “Experimental Drug: Hydromorphone Hydrochloride Injection.” NCT05579223 ↗ |
| Known as | HYDROMORPHONE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | IDS-NH-004 | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | IVH | “OBJECTIVE: Intranasal fentanyl (INF) quickly and noninvasively relieves severe pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires...” PMID 32649717 ↗ Jul 2020 |
| Known as | Jurnista | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | N02AA03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | NMED-1077 | “This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗ |
| Known as | Novolaudon | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | NSC-117862 | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | NSC-19046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | OROS hydromorphone | “The purpose of this study is to investigate the pharmacokinetics of OROS hydromorphone in healthy adult Taiwanese participants after the oral administration of a single 16 mg dose.” NCT01487564 ↗5“This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗ “OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg” NCT00631319 ↗ “The equianalgesic doses were 16 mg OROS hydromorphone and 40 mg SR oxycodone (median values).” PMID 20384968 ↗ Sep 2010 “OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks” NCT00980798 ↗ “16 mg OROS hydromorphone under fasting conditions” PMID 17270055 ↗ Feb 2007 |
| Known as | OROS hydromorphone (slow release) | “OROS hydromorphone (slow release) 8 mg and 16 mg tablets and placebo taken orally once daily” NCT00411164 ↗1“OROS hydromorphone (slow release) in patients with chronic cancer pain” NCT00410787 ↗ |
| Known as | OROS hydromorphone ER | “OBJECTIVE: This multicenter, double-blind, placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER...” PMID 20429852 ↗ Jun 2010 |
| Known as | OROS Hydromorphone HCI | “OROS Hydromorphone HCI (slow release)” NCT00411034 ↗ |
| Known as | OROS hydromorphone HCI (slow release) | “At the end of the washout period, all patients received OROS hydromorphone HCI (slow release) 8 mg or matching placebo to be taken once daily.” NCT00411164 ↗2“OROS hydromorphone HCI (slow release) tablets in 8, 16, 32 and 64mg doses administered orally every 24 hours” NCT00410787 ↗ “OROS Hydromorphone HCI (slow release)” NCT00410878 ↗ |
| Known as | OROS Hydromorphone HCI SR (slow release) | “OROS Hydromorphone HCI SR (slow release)” NCT00410943 ↗ |
| Known as | OROS hydromorphone HCL | “This was a multicenter, open-label, randomized (patients are assigned different treatments based on chance), dose-titration, parallel-group study characterizing the...” NCT00399048 ↗2“OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks” NCT00980798 ↗ “OROS hydromorphone HCL slow release 8, 16, 32, and 64mg tablets” NCT00410540 ↗ |
| Known as | OROS hydromorphone hydrochloride (HCl) | “This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗1“Oral Osmotic Therapeutic System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in participants with cancer-related pain.” NCT01205126 ↗ |
| Known as | Palladone | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Known as | Palladone-sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗ |
| Action | Activate | “as well as intramuscular hydromorphone as an opioid agonist control (2, 4 mg) and placebo” PMID 10928310 ↗ Mar 20001“Mu opioid receptor agonist” CHEMBL398707 ↗ |
| Modality | Other / unclassified | “both opioids” PMID 40493496 ↗ Jun 2025 |
| Route | Other | “hydromorphone bolus injection through an epidural catheter” NCT00003115 ↗ |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL398707 ↗ |